Company research
Eikon Therapeutics, Inc.
CIK 1861123Updated Nov 13, 2026
SecurityEIKN · NASDAQ · equity
EIKN price & chart
Loading TradingView…
NASDAQ:EIKN on TradingView ↗About the company
We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications. We believe our product candidates reflect strong scientific and clinical potential and could eventually become critical medicines in the treatment paradigm of various cancers.
In the news
Eikon Therapeutics to Participate in Investor Conferences in September 2026 ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
SCHEDULE 13G/A - filed by FMR LLC regarding Eikon Therapeutics, Inc.
Show 5 more recent filings
SCHEDULE 13G/A - filed by Abu Dhabi Investment Authority regarding Eikon Therapeutics, Inc.
Regulation FD Disclosure
Items 7.01, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Offerings
Registration 333-292633
- Gross proceeds
- 381196800.0
- Net proceeds
- 354513024.0
- Deal price
- 18.0
- Shares
- 21177600
- Offering price
- $18.00
- Ticker
- EIKN
Underwriters: J.P. Morgan*, Morgan Stanley*, BofA Securities, Mizuho
Registration 333-293213
Filing attachments
eikn-ex99_1.htm · 8-K · 2026-11-12
Exhibit 99.1 Eikon Therapeutics Reports Third Quarter 2026 Financial Results and Provides Clinical Updates • Presented seven posters at the 2026 European Society for Medical Oncology (ESMO) Congress highlighting progress across the oncology portfolio, including clinical data from Eikon’s PARP1-selective inhibitor and Werner (WRN) helicase inhibitor programs and updated EIK1001 data from TeLuRide-005, a Phase 2 trial in non-small cell lung cancer (NSCLC) • Dosed first patient in TeLuRide-008,…
Read attachment ↗eikn-ex99_1.htm · 8-K · 2026-10-26
Exhibit 99.1 Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress • TLR7/8 dual-agonist EIK1001 plus pembrolizumab and chemotherapy in first-line, stage 4 non-small cell lung cancer (NSCLC) demonstrates durable effect in combination with standard-of-care, and a tolerability profile supportive of systemic administration in an outpatient setting • With median follow-up of 12.7 months, objective response rate (ORR) for the squam…
Read attachment ↗eikn-ex99_1.htm · 8-K · 2026-10-23
Exhibit 99.1 Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress • Initial and updated cohort data from ongoing Phase 1/2 study of highly selective non-brain-penetrant PARP1 inhibitor EIK1003 continue to support potentially differentiated profile of EIK1003 in combination strategies within the PARP inhibitor landscape • Initial results from ongoing Phase 1/2 study of highly selective CNS-penetrant PARP1 inhibito…
Read attachment ↗eikn-ex99_1.htm · 8-K · 2026-08-14
EX-99.1 2 eikn-ex99_1.htm EX-99.1 Q3 Company Update August 2026 Exhibit 99.1 Disclaimer Any statements made in this presentation that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning the strategy, initiation, cost, timing, progress, and results of our preclinical studies and clinical trials for our product candidates; our ab…
Read attachment ↗eikn-ex99_1.htm · 8-K · 2026-08-13
EX-99.1 2 eikn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates • Eikon announced seven abstracts accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026 highlighting progress across Eikon’s oncology portfolio, including clinical updates for EIK1001 and EIK1003 and initial clinical findings for EIK1004 and EIK1005 • Presented data at the American Society for Clinical…
Read attachment ↗eikn-ex99_1.htm · 8-K · 2026-06-01
EX-99.1 2 eikn-ex99_1.htm EX-99.1 Q2 Company Update June 2026 Disclaimer Any statements made in this presentation that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning the strategy, initiation, cost, timing, progress, and results of our preclinical studies and clinical trials for our product candidates; our ability to levera…
Read attachment ↗